Last reviewed · How we verify
OPDUALAG (RELATLIMAB-RMBW)
OPDUALAG (generic name: RELATLIMAB-RMBW) is a Programmed Death Receptor-1 Blocking Antibody [EPC] drug developed by BRISTOL MYERS SQUIBB. It is currently FDA-approved for Advanced melanoma with tumour cell PD-L1 expression below 1%, Unresectable or metastatic melanoma.
Relatlimab is an antibody that inhibits the lymphocyte activation gene 3 protein, a class of inhibitor drugs. It is being studied in clinical trials for the treatment of melanoma, including advanced melanoma, metastatic melanoma, and liver metastases, often in combination with other immune checkpoint inhibitors.
At a glance
| Generic name | RELATLIMAB-RMBW |
|---|---|
| Sponsor | BRISTOL MYERS SQUIBB |
| Drug class | Programmed Death Receptor-1 Blocking Antibody [EPC] |
| Target | Lymphocyte activation gene 3 protein |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Advanced melanoma with tumour cell PD-L1 expression below 1%
- Unresectable or metastatic melanoma
Common side effects
- Musculoskeletal pain
- Fatigue
- Rash
- Pruritus
- Diarrhea
- Nausea
- Headache
- Hypothyroidism
- Decreased appetite
- Cough
- Decreased hemoglobin
- Decreased lymphocytes
Serious adverse events
- Adrenal insufficiency
- Anemia
- Colitis
- Pneumonia
- Acute myocardial infarction
- Back pain
- Myocarditis
- Pneumonitis
- Hemophagocytic lymphohistiocytosis
- Acute edema of the lung
Key clinical trials
- Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High Risk Melanoma (Phase 2)
- A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous an (Phase 2)
- A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma (Phase 3)
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (Phase 1)
- Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors (Phase 1)
- Dose-response Analysis of Nivolumab/Relatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participan (N/A)
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously (Phase 3)
- A Phase II Trial of Personalized Immunotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck That Have Progressed on Prior Immunotherapy (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OPDUALAG CI brief — competitive landscape report
- OPDUALAG updates RSS · CI watch RSS
- BRISTOL MYERS SQUIBB portfolio CI
Frequently asked questions about OPDUALAG
What is OPDUALAG?
What is OPDUALAG used for?
Who makes OPDUALAG?
What is the generic name of OPDUALAG?
What drug class is OPDUALAG in?
What development phase is OPDUALAG in?
What are the side effects of OPDUALAG?
What does OPDUALAG target?
Related
- Drug class: All Programmed Death Receptor-1 Blocking Antibody [EPC] drugs
- Target: All drugs targeting Lymphocyte activation gene 3 protein
- Manufacturer: BRISTOL MYERS SQUIBB — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced melanoma with tumour cell PD-L1 expression below 1%
- Indication: Drugs for Unresectable or metastatic melanoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing